(Total Views: 537)
Posted On: 05/07/2020 1:03:58 PM
Post# of 149086
“I agree 100%. In fact I feel like a broken record. Completing the enrollment is the most important near term step, and its not even close.
I agree 100% with your 100% agreement. And I believe NP and CYDY agree as well. In one of the videos or phone calls last week said something to the nature of, “We’re not focusing that much on the severe trial but we’re focusing on getting as many sites open as possible for the phase 2 mild/moderate.”
Remdesevir has set a low bar and leronlimab can far exceed that bar with placebo controlled data. The question is: how will the FDA view data from 75 patients? Are they going to request a larger phase 3?
I agree 100% with your 100% agreement. And I believe NP and CYDY agree as well. In one of the videos or phone calls last week said something to the nature of, “We’re not focusing that much on the severe trial but we’re focusing on getting as many sites open as possible for the phase 2 mild/moderate.”
Remdesevir has set a low bar and leronlimab can far exceed that bar with placebo controlled data. The question is: how will the FDA view data from 75 patients? Are they going to request a larger phase 3?
(0)
(0)Scroll down for more posts ▼
